Immuno-oncology 2017 Congress conference -May 1 2017

[D.ap]

Any one know any of these oncologist to ask about Keytruda possibly being FDA approved to used with ASPS?

Biomarkers & Immuno-Oncology World Congress 2017

10:45 The Evolving Role of Immune Checkpoint Therapy in Colorectal Cancer with and without Deficient Mismatch Repair
Michael J. Overman, M.D., Associate Professor, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
Immune checkpoint therapy targeting PD-1/PD-L1 has shown robust activity in colorectal cancer with mismatch deficiency or microsatellite instability (MSI-high) but not microsatellite stable (MSS) colorectal cancer. It is now clear that MSI-high cancers represent a unique molecular tumor subset that should be approached with immune-based therapy. This talk will discuss the current combinatorial efforts within MSI-high colorectal cancer and also the emerging combinations that are being explored in MSS colorectal cancer.


10:15 RNA, DNA or Protein? Or All Three? Development of Multiple Diagnostics Predicting Response to Pembrolizumab
Matt Marton, Ph.D., Director, Genomics and Companion Diagnostics, Translational Biomarkers, Merck
An effective diagnostic strategy for anti-PD1 therapy may require multiple predictive biomarkers that assess the complexity of both tumor biology and the immune system. In addition to PD-L1 protein expression, multiple biomarkers, including gene expression and mutation burden, have been proposed as predictors of response to anti-PD1 therapy. We will discuss analytical performance characteristics of potential diagnostic devices under development, including an RNA-based gene expression device being studied in multiple indications.



http://www.biomarkerworldcongress.com/Immunotherapy/